Conference Coverage

Eteplirsen showed safety, efficacy over 2 years in Duchenne muscular dystrophy


 

AT THE AAN 2014 ANNUAL MEETING

"The reason that this is important is there has actually been very little human data until recently, despite the fact that [PMOs have] been around for over 30 years. Most of the work has been done in animals and in research laboratories, and it’s only until recently that people have been exposed to the drug," Dr. Kaye said.

The study was funded by Sarepta Therapeutics. Dr. Kaye and two coauthors are employees of the company. Dr. Mendell had no relevant disclosures.

jevans@frontlinemedcom.com

Pages

Recommended Reading

FDA requires stronger peripheral neuropathy warning for quinolones
MDedge Neurology
PML reported in multiple sclerosis patient on fingolimod
MDedge Neurology
Limited data support multiple myositis treatment options
MDedge Neurology
Autoantibodies play role in myositis classification, treatment
MDedge Neurology
Consider small-fiber neuropathies in systemic lupus erythematosus
MDedge Neurology
Corneal nerve fiber loss may predict diabetic neuropathy
MDedge Neurology
West Nile virus has cost the United States nearly $800 million
MDedge Neurology
Pseudobulbar affect: More common than you’d think
MDedge Neurology
VIDEO: Oocyte modification might prevent mitochondrial diseases
MDedge Neurology
FDA panel considers human studies of modified oocytes for preventing disease
MDedge Neurology